Oxford Biomedica plc (LON:OXB)
London · Delayed Price · Currency is GBP · Price in GBX 487.00
-0.50 (-0.10%)
Aug 14, 2026, 5:07 PM GMT
Oxford Biomedica Ratios and Metrics
Market cap in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 589 | 744 | 445 | 213 | 426 | 1,059 | |
Market Cap Growth | 25.01% | 67.15% | 108.92% | -50.00% | -59.79% | 24.98% |
Enterprise Value | 641 | 795 | 479 | 223 | 453 | 1,008 |
Last Close Price | 4.87 | 6.17 | 4.20 | 2.20 | 4.42 | 12.30 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 55.72 |
Forward PE | - | 113.10 | 113.10 | 113.10 | 113.10 | 60.29 |
PS Ratio | 3.49 | 4.41 | 3.46 | 2.38 | 3.04 | 7.42 |
PB Ratio | 6.45 | 8.14 | 7.36 | 2.74 | 1.80 | 5.66 |
P/TBV Ratio | 8.91 | 11.24 | 15.99 | 4.95 | 4.31 | 5.66 |
P/FCF Ratio | - | - | - | - | - | 66.23 |
P/OCF Ratio | 1162.64 | 1466.91 | - | - | - | 41.62 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.80 | 4.71 | 3.72 | 2.49 | 3.24 | 7.06 |
EV/EBITDA Ratio | - | - | - | - | - | 30.85 |
EV/EBIT Ratio | - | - | - | - | - | 45.53 |
EV/FCF Ratio | - | - | - | - | - | 63.01 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.62 | 1.62 | 1.80 | 1.43 | 0.48 | 0.05 |
Debt / EBITDA Ratio | - | - | - | - | - | 0.27 |
Debt / FCF Ratio | - | - | - | - | - | 0.58 |
Net Debt / Equity Ratio | 0.56 | 0.56 | 0.80 | 0.10 | -0.11 | -0.53 |
Net Debt / EBITDA Ratio | -2.80 | -2.80 | -2.01 | -0.11 | 0.87 | -3.05 |
Net Debt / FCF Ratio | -12.04 | -12.04 | -0.83 | -0.20 | 0.93 | -6.23 |
Asset Turnover | 0.61 | 0.61 | 0.53 | 0.25 | 0.40 | 0.68 |
Inventory Turnover | 6.65 | 6.65 | 5.73 | 3.91 | 6.40 | 7.32 |
Quick Ratio | 1.92 | 1.92 | 1.98 | 2.80 | 3.33 | 4.54 |
Current Ratio | 2.20 | 2.20 | 2.28 | 3.19 | 3.61 | 4.92 |
Return on Equity (ROE) | -40.37% | -40.37% | -70.28% | -117.29% | -21.32% | 12.67% |
Return on Assets (ROA) | -6.98% | -6.98% | -10.54% | -15.07% | -8.33% | 6.57% |
Return on Invested Capital (ROIC) | -21.81% | -24.77% | -42.05% | -58.29% | -31.30% | 25.31% |
Return on Capital Employed (ROCE) | -12.90% | -12.90% | -23.60% | -41.30% | -11.60% | 10.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -5.11% | -4.05% | -9.71% | -73.95% | -9.19% | 1.80% |
FCF Yield | -0.72% | -0.57% | -13.07% | -18.01% | -6.79% | 1.51% |
Buyback Yield / Dilution | -8.18% | -8.18% | -7.15% | -1.82% | -10.76% | -7.10% |